Subsequent Events	3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events ATM As of May 8, 2024, the Company has sold 931,910 additional shares under the ATM Sales Agreement, for net proceeds of $141,320 after payment of commission and fees of $2,884. Common Stock Offering As of April 23, 2024, the Company entered into an underwritten Agreement with Aegis Capital Corp. (“Aegis”), pursuant to which Aegis acted as the Company’s underwriter on a firm commitment basis in connection with the sale by the Company of an aggregate of 50,000,000 shares of common stock in a public offering, which included: (i) 19,800,000 shares of common stock, and (ii) pre-funded warrants to purchase 30,200,000 shares of common stock. The Pre-Funded Warrants had a nominal exercise price of $0.00001. Each share of common stock was sold at an offering price of $0.10, and each Pre-Funded Warrant was sold at an offering price of $0.09999. The offering closed on April 25, 2024. On May 3, the Company closed on the sale of an additional 2,040,000 shares of common stock, upon exercise by the underwriter of the over-allotment option. The Company received gross proceeds of approximately $5.2 million before deducting transaction related expenses payable by the Company. All commissions, qualified legal, accounting, registration and other direct costs of $0.6 million related to the public offering were offset against the gross proceeds. The Company is using the net proceeds to fund its cash needs. Israeli Entity As of May 8, 2024, the Company is in the process of creating a wholly-owned entity in Israel for continued research and development efforts.

Subsequent Events

3 Months Ended

Mar. 31, 2024

14. Subsequent Events

ATM

As of May 8, 2024, the Company has sold 931,910 additional shares under the ATM Sales Agreement, for net proceeds of $141,320 after payment of commission and fees of $2,884.

Common Stock Offering

As of April 23, 2024, the Company entered into an underwritten Agreement with Aegis Capital Corp. (“Aegis”), pursuant to which Aegis acted as the Company’s underwriter on a firm commitment basis in connection with the sale by the Company of an aggregate of 50,000,000 shares of common stock in a public offering, which included: (i) 19,800,000 shares of common stock, and (ii) pre-funded warrants to purchase 30,200,000 shares of common stock. The Pre-Funded Warrants had a nominal exercise price of $0.00001. Each share of common stock was sold at an offering price of $0.10, and each Pre-Funded Warrant was sold at an offering price of $0.09999. The offering closed on April 25, 2024.

On May 3, the Company closed on the sale of an additional 2,040,000 shares of common stock, upon exercise by the underwriter of the over-allotment option.

The Company received gross proceeds of approximately $5.2 million before deducting transaction related expenses payable by the Company. All commissions, qualified legal, accounting, registration and other direct costs of $0.6 million related to the public offering were offset against the gross proceeds. The Company is using the net proceeds to fund its cash needs.

Israeli Entity

As of May 8, 2024, the Company is in the process of creating a wholly-owned entity in Israel for continued research and development efforts.